GIA
LUMO

Gargoyle Investment Advisor’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Gargoyle Investment Advisor’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,363
Closed -$440K – 181
2015
Q3 		$440K Sell
1,363
-147
-10% -$64.6K 0.18% 148
2015
Q2 		$602K Buy
1,510
+227
+18% +$96.5K 0.23% 124
2015
Q1 		$632K Buy
+1,283
New +$497K 0.24% 119

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Gargoyle Investment Advisor's LUMO Position: Q4 2015 in Review

Gargoyle Investment Advisor sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2015, closing a stake of 1,363 shares — an estimated $440K sold.

Gargoyle Investment Advisor first reported a position in LUMO in Q1 2015 and held it in 3 quarters. The position peaked at $632K in Q1 2015. 152 funds tracked by Wall St. Rank hold LUMO as of Q4 2015.

  • Gargoyle Investment Advisor reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Gargoyle Investment Advisor sold 1,363 Lumos Pharma, Inc. Common Stock shares in Q4 2015, an estimated $440K.
  • Gargoyle Investment Advisor first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2015 and held it in 3 quarters.
  • Gargoyle Investment Advisor's Lumos Pharma, Inc. Common Stock position peaked at $632K in Q1 2015.
  • 152 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2015.

Based on Gargoyle Investment Advisor's 13F filing for Q4 2015, filed 27 Jan 2016.